Farr Miller & Washington LLC DC increased its position in shares of Danaher Corporation (NYSE:DHR) by 0.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 256,897 shares of the conglomerate’s stock after purchasing an additional 1,036 shares during the quarter. Danaher accounts for approximately 2.1% of Farr Miller & Washington LLC DC’s investment portfolio, making the stock its 25th largest position. Farr Miller & Washington LLC DC’s holdings in Danaher were worth $22,037,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Johnson Financial Group Inc. lifted its holdings in shares of Danaher by 70.7% in the third quarter. Johnson Financial Group Inc. now owns 3,929 shares of the conglomerate’s stock worth $337,000 after acquiring an additional 1,627 shares during the last quarter. Destination Wealth Management lifted its holdings in shares of Danaher by 1.9% in the third quarter. Destination Wealth Management now owns 112,567 shares of the conglomerate’s stock worth $9,656,000 after acquiring an additional 2,129 shares during the last quarter. Marshall & Sullivan Inc. WA lifted its holdings in shares of Danaher by 1.9% in the third quarter. Marshall & Sullivan Inc. WA now owns 37,336 shares of the conglomerate’s stock worth $3,445,000 after acquiring an additional 711 shares during the last quarter. Reynders McVeigh Capital Management LLC lifted its holdings in shares of Danaher by 8.2% in the third quarter. Reynders McVeigh Capital Management LLC now owns 193,293 shares of the conglomerate’s stock worth $16,581,000 after acquiring an additional 14,675 shares during the last quarter. Finally, Iberiabank Corp bought a new position in shares of Danaher in the third quarter worth about $381,000. 76.32% of the stock is owned by institutional investors and hedge funds.
DHR has been the subject of a number of research reports. J P Morgan Chase & Co reissued an “overweight” rating and issued a $95.00 target price on shares of Danaher in a report on Friday, September 8th. Goldman Sachs Group reissued a “neutral” rating and issued a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th. Cowen reissued a “buy” rating and issued a $90.00 target price on shares of Danaher in a report on Wednesday, October 4th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a report on Thursday, October 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $95.00 target price (up previously from $86.00) on shares of Danaher in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $93.31.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $0.87 EPS. equities analysts expect that Danaher Corporation will post 3.99 earnings per share for the current year.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Robert S. Lutz sold 11,189 shares of the stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the sale, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is owned by company insiders.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
What are top analysts saying about Danaher Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Danaher Corporation and related companies.